

U.S. Food and Drug Administration



CENTER FOR BIOLOGICS EVALUATION AND RESEARCH

FDA Home Page | CBER A-Z Index | CBER Search | Contact CBER | CBER Home Page

Blood | Vaccines | Cellular/Gene Therapy | Tissue | Devices Products | Industry | Healthcare | Reading Room | Meetings | What's New

Approval Times

The Center for Biologics Evaluation and Research continues to ensure the safety of the nation's blood supply and the safety and efficacy of counter-terrorism and other vaccines and antitoxins, as well as cutting edge technologies such as somatic cell and gene therapies. CBER also continues to approve new biological licenses as well as biological license supplements.

Approval Times for Priority and Standard Biological License Applications and Device Applications

	BLAs						PMAs		510ks	
Calendar Year	Priority Review		Standard Review		Blood Banking		Number	Median	Number	Median
	Number Approved	Median Total Approval Time (months)	Number Approved	Median Total Approval Time (months)	Number Approved	Median Total Approval Time (months)	Approved	Total Approval Time (months)	Approved	Total Approval Time (months)
1995	2	50.37	16	34.42	11	10.13	0		51	6.7
1996	3	11.87	24	39.63	10	10.18	3	11.7	31	5.0
1997	7	8.94	22	22.07	8	10.99	0		46	11.1
1998	8	6.91	13	23.42	6	11.94	0		52	15.1
1999	3	13.87	4	24.18	3	8.32	2	24.7	44	7.0

2000	1	8.52	9	28.67	2	16.80	0		22	3.3
2001	2	13.18	8	23.74	5	16.63	3	10.5	25	5.5
2002	6	14.69	10	19.91	4	10.61	2	19.9	42	6.2
2003	5	22.18	11	30.00	6	8.66	3	8.5	47	2.3
2004*	0		2	19.77	2	12.91	1	5.9	62	2.5

^{*} Beginning in 2004, these figures exclude BLAs for therapeutic biological products transferred from CBER to CDER effective 10/1/2003.

Description of approval time information

Transfer of therapeutic products from CBER to CDER

Updated June 29, 2005

CBER Home Page | CBER A-Z Index | CBER Search | Contact CBER FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA | Privacy | Accessibility | HHS Home Page

FDA / Center for Biologics Evaluation and Research